{"name":"Hong Kong Nasopharyngeal Cancer Study Group Limited","slug":"hong-kong-nasopharyngeal-cancer-study-group-limited","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Docetaxel, Cisplatin, 5-FU and Cetuximab","genericName":"Docetaxel, Cisplatin, 5-FU and Cetuximab","slug":"docetaxel-cisplatin-5-fu-and-cetuximab","indication":"Locally advanced or metastatic non-small cell lung cancer, Locally advanced or metastatic breast cancer, Colorectal cancer, Head and neck cancer","status":"phase_2"}]}],"pipeline":[{"name":"Docetaxel, Cisplatin, 5-FU and Cetuximab","genericName":"Docetaxel, Cisplatin, 5-FU and Cetuximab","slug":"docetaxel-cisplatin-5-fu-and-cetuximab","phase":"phase_2","mechanism":"Docetaxel inhibits microtubule dynamics, Cisplatin induces DNA crosslinks, 5-FU inhibits thymidylate synthase, and Cetuximab binds to the epidermal growth factor receptor.","indications":["Locally advanced or metastatic non-small cell lung cancer, Locally advanced or metastatic breast cancer, Colorectal cancer, Head and neck cancer","Metastatic nasopharyngeal carcinoma"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi1wJBVV95cUxOVUg2OW5qTE13aWhtUmpsTnU4Skx5REhiLW95WjVRdzQzZE1wMHRtb0ZsanVPVmlHREUycGhnUDBUb0F4ZjlLcFdtME8yeGZvcWRlcjBLOW1HVFJEUy1xV0xMVERaTWFFc1M5ZWdkc1pjVDYwYWhwN0NZZEZmQkRtVTUtWmJyWm40VUxHS3VnaGVQdW53cE9IR3Y5Wm1NY3BqUlN5d2pfaHE1TDlkNVpGUHRySWlIcXN3S1BfLWgyWmJDNy1RXzRqUFhUYVRXMm9qSDQ0T3lhSzY3LTNlZjBta1RIYlcyQ2tGYjhLV24yREdRTVl3bWhVMlV0TWI0MWF0dXc5TVJBejBrcHNYWkZob3Y1MTROelVwVnE3cGN2N1ZoNFZBR0JSNFRuQ1JNTnVKbjdLR2pjMVFDbmR3T21yaFJQN05LS2FFN2NRRHU4UlFac0VBYkNN?oc=5","date":"2026-01-04","type":"trial","source":"GlobeNewswire","summary":"HUTCHMED Initiates Phase III Stage of the Ongoing Trial of - GlobeNewswire","headline":"HUTCHMED Initiates Phase III Stage of the Ongoing Trial of","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxPbHVxNF9YUW1vWUpZMW5OYnctaURBS0oxYmpPbkI0QjY3aTlJLTE4eTNMQ3FzZF9DLXEweUtuXzlMVHpUSDdOR1RnUWJwcXpISE1IeG9QZGE3a1I1WjRMeTB2eXI2WkZPTm4wallJc3V6TW42Mmtic1ZUMnJuNkhZT0lnSGtQMXhBSGRtX2RKT0pJMEw0ZWtYWTVrNmZTdU5rWFZOLVViRlVuWnRibUtSOXJZRmxTeVU?oc=5","date":"2025-10-22","type":"pipeline","source":"BioSpace","summary":"Largest Milestone Payment Secured: Biokin, a Rising Chinese Pharmaceutical MNC - BioSpace","headline":"Largest Milestone Payment Secured: Biokin, a Rising Chinese Pharmaceutical MNC","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAJBVV95cUxNRWVOdkN0X0lFNWNEemZUdXE0SkpXaks0V1gzWFF3VGw3aHNQRlo4Z2NWbEl3c0xkdHVESlIxcFNUM21NZDNMS2tMZVBPU003TnJiazRVQ2VjSTVJT1lPWG9JUTNZNWJTTEg2TVNSdFpPbXBqY0pCRG1jQl82MUx4akpmMC0tMUJoSVhuOTEyT2VXT3piNk9pSW8ybjIzcC1GMXIwVVR3YW1FS0VVU0Utbm93dF94QWkxdFVGY2d4a1JzMGVMYVhKUURBcnE2QkNRcVAzZzNNSG1XT2FWS0RVMkJRSmp1U3p0MGFZdmZYeEpIdkJLNEc5UkNjdVVDSzBvSVVnVVA0NHo1cHJ1VUdRT2xIeU9iMW9naURKMmh6MnBpRnBLQzFvb2NJUF8?oc=5","date":"2025-05-19","type":"trial","source":"The Chinese University of Hong Kong","summary":"CUHK-led multinational study shows new China-developed cancer drug D3S-001 is effective in treating solid tumours, including lung, colorectal and pancreatic cancer - The Chinese University of Hong Kon","headline":"CUHK-led multinational study shows new China-developed cancer drug D3S-001 is effective in treating solid tumours, inclu","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE5tT0E5VmhqSEFOODF4NVd6MzlxT2xxSWxCUGZhNGhmdm1wbFltT1hqLVR1dF9wTThGbDFuY3hlNzJfd0ZIUUxuWVdDS2c1cGpQdWk0LWpiS0RzQjRRejZr?oc=5","date":"2025-04-22","type":"pipeline","source":"HKTDC Research","summary":"Biotechnology, Medical & Healthcare Industry in Hong Kong - HKTDC Research","headline":"Biotechnology, Medical & Healthcare Industry in Hong Kong","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2024-12-09","type":"pipeline","source":"The Chinese University of Hong Kong","summary":"CU Medicine and CTTQ sign a Cooperation Framework Agreement Leverage the strengths of mainland China and Hong Kong in pharmaceutical innovations, talent development & commercialisation of medical prod","headline":"CU Medicine and CTTQ sign a Cooperation Framework Agreement Leverage the strengths of mainland China and Hong Kong in ph","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxNMDNmQXJYTEwtTUo2aUlPamlpR19OaDNYc0ZYclVPaUUxWkNTam1QU0tVOTVhWXFkZmc0bVBKQ3pjTlRZTk1RYUFxN1NtcUlzSUZoWHA2dTFKOUY2ODhkMHg2ZVZCQ0JVSVNEVnhJWFozZjdFNnNITi1wT1MxbnhuQ0kwNUUySkVLOXlZOWY0T2xfMU1BaDMxalVSSE4?oc=5","date":"2023-12-12","type":"regulatory","source":"South China Morning Post","summary":"FDA-approved Chinese cancer drug to cost 30 times more - South China Morning Post","headline":"FDA-approved Chinese cancer drug to cost 30 times more","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiswJBVV95cUxOa2dGWEVIbVFNZl9YLWZBZ1dKV2dPMUxWOVhDcjc3dDNmNFZmdWs2RDdOdkFVX09pb3d3VXA3d1U3czdrcVJJSzdqMG9fb2VzNnd0Rks0dFBwYVNHVkNXUnFoMGpwdVBhQzFuWW5xckt3S2lkOXhhVkwwOXRkbF9Sc2J0VDFNb3k0aEk4VXc5eG9nVllZckJNT29maXQ0TDJ0cGVrQ1YtcnBJSEZwUWFNeWVkMHVBdXhQNlgtQ1J0RGdiMDZpQ3FDTVliLTItak1GaS1naHFnbVRObEMzS0J0YWQ1ZkNyRHpoTmJzbWx2d1QtU0NubGVyUUdiWTY1SUlHaGhhd0lMTVlFUDg3MjE2WUlGU3lTWk9fTC1WWl83VVBBRTBLcG5heEF6ajBXRlJ1aXdJ?oc=5","date":"2023-04-11","type":"deal","source":"PR Newswire","summary":"Specialised Therapeutics signs partnership agreement with Akeso Inc. and CTTQ-Akeso to commercialise new anti-PD1 antibody in Australia and Southeast Asia - PR Newswire","headline":"Specialised Therapeutics signs partnership agreement with Akeso Inc. and CTTQ-Akeso to commercialise new anti-PD1 antibo","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTFBFSXBCZUdUczBwZ08wa0o2b3dxR0tHZVFOSW1fVDZXYTVxNXhNSUg0T1JlUy1KTmVKSTBudUI2M1lGZVAwU2hIVjRxZ0pYaGI4TU0w?oc=5","date":"2023-03-31","type":"pipeline","source":"FirstWord Pharma","summary":"Sino Biopharm (1177.HK) Announces 2022 Annual Results - FirstWord Pharma","headline":"Sino Biopharm (1177.HK) Announces 2022 Annual Results","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYkFVX3lxTE4wc0ZmeW9fdUVSNDVoQVdzTjVxWHRfMzcyUWdwaGZ0LVhNTVUwQWo3bE1uZ29lcmFzZ3RzYklDX0NTZ2RXb0JFQmVKc3hlZDVLWC15VEFxOFd3Ni1GY2dMV3FR?oc=5","date":"2021-08-21","type":"pipeline","source":"康方生物","summary":"Akeso Shipped off its First Batch of Penpulimab Monoclonal Antibody Injection (安尼可®) - 康方生物","headline":"Akeso Shipped off its First Batch of Penpulimab Monoclonal Antibody Injection (安尼可®) - 康方生物","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFBpdW13X1QwRzRmSEo4UFVlZkZRendNWHVSVFBoS3Z2VlVzdG1iclVzVEZlTDBma2oyX3J3eDRmWENTLWVmNm80SjlEWHV4Q1Nwem9FUW5NODBGUjdCV3VN?oc=5","date":"2021-07-07","type":"pipeline","source":"Nature","summary":"Whole-genome profiling of nasopharyngeal carcinoma reveals viral-host co-operation in inflammatory NF-κB activation and immune escape - Nature","headline":"Whole-genome profiling of nasopharyngeal carcinoma reveals viral-host co-operation in inflammatory NF-κB activation and ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE9yVXI5M3haQUhrZE9VeE9rYTNUU2hib0JHYTFuRWVodmlkWExBbVhJZ1RMa3h1WmpMVWxkTVV0UnN6eEpVMmc3SV9EYi1VSVFFdXlfOTFRZTVCQXpFT05R?oc=5","date":"2020-11-26","type":"pipeline","source":"Nature","summary":"Head and neck squamous cell carcinoma - Nature","headline":"Head and neck squamous cell carcinoma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMieEFVX3lxTE1Mb0REVGt6WWJCTlRfRG5PNTZrSUZJVTZIU1NWOXdkSzNkend0elpjcVdkUGo1UmdLQTMyM2RzZ2dXOUUyRDNlUkNDZklWa1hlWXVWZmNLSUlva2xvdTFzckVNMmRmbllPOVJ1TlNaQWVmSW9zNlJNZQ?oc=5","date":"2020-11-10","type":"pipeline","source":"Fierce Pharma","summary":"10 biotechs to know in China - Fierce Pharma","headline":"10 biotechs to know in China","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}